Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADR-001 in Severe COVID-19 Pneumonia
NCT04888949Phase 2Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ADR-001 in COVID-19 pneumonia, sponsored by Rohto Pharmaceutical Co., Ltd.. Started Jun 2021; status: completed.
02
Drugs
ADR-001
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04888949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888949.